Endologix Honors Innovators of Aortic Therapy at VEITHsymposium
November 15 2018 - 5:00PM
Business Wire
Endologix, Inc. (NASDAQ: ELGX), a developer and marketer of
innovative treatments for aortic disorders, today honored four
innovators of aortic therapy at the 45th Annual Symposium on
Vascular and Endovascular Issues, Techniques, Horizons
(VEITHsymposium®), a meeting of endovascular specialists
highlighting developments in the treatment of vascular disease.
At an event called “Learning from the Past to Shape the Future:
Evolution of Aortic Therapy,” Endologix recognized the surgeons who
advanced aortic repair therapy and initiated early randomized
controlled trials of endovascular aneurysm repair (EVAR). Prior to
the early 1990s, patients who were not eligible for open surgical
repair were left untreated until early innovators challenged the
status quo and developed endovascular grafts.
“Randomized controlled trials are the gold standard for
evaluating any therapy, and several of our honorees led studies
that helped set the standard for the entire EVAR category,” said
Matt Thompson, MD, Chief Medical Officer of Endologix. “These
innovators revolutionized the treatment of abdominal aortic
aneurysms, and we are proud to recognize the work they are doing to
advance the field of vascular surgery. To advance the standard of
care, we believe future products must be evaluated for superior
outcomes as compared to conventional EVAR grafts.”
The distinguished honorees were:
- Jean-Pierre Becquemin, MD, study
chair of the ACE trial;
- Jan Blankensteijn, MD, principal
investigator of the DREAM trial;
- Roger Greenhalgh, MD, leader of
the EVAR-1 trial;
- Frank Veith, MD, leader of the
team that performed the first EVAR procedure in the United States
in 1992, setting the course for clinical studies and therapeutic
advances that would define the EVAR category.
Other physicians acknowledged for their substantial
contributions included Ted Diethrich, MD, Roy Greenberg, MD, Frank
Lederle, MD, Michael Marin, MD, Juan Parodi, MD, and Nikolai
Volodos, MD.
About VEITH symposium
The VEITH symposium provides a unique and exciting format to
learn the most current information about what is new and important
in the treatment of vascular disease. The five-day event features
rapid-fire presentations from world-renowned vascular specialists
with emphasis on the latest advances, changing concepts in
diagnosis and management, pressing controversies, and new
techniques. For more information, visit www.veithsymposium.org.
About Endologix, Inc.
Endologix, Inc. develops and manufactures minimally
invasive treatments for aortic disorders. The Company's focus is in
endovascular stent grafts for the treatment of abdominal aortic
aneurysms (AAA). AAA is a weakening of the wall of the
aorta, the largest artery in the body, resulting in a balloon-like
enlargement. Once an AAA develops, it continues to
enlarge and, if left untreated, becomes increasingly susceptible to
rupture. The overall patient mortality rate for
ruptured AAA is approximately 80%, making it a leading
cause of death in the U.S. For more information,
visit www.endologix.com.
Cautions Regarding Forward-Looking Statements
Except for historical information contained herein, this press
release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995. These
forward-looking statements generally can be identified by the use
of words such as “anticipate,” “expect,” “could,” “may,” “will,”
“believe,” “estimate,” “forecast,” “goal,” “project,” "continue,"
"outlook," “guidance,” "future,” other words of similar meaning and
the use of future dates. Forward-looking statements used in this
press release include Endologix’s commitment to investing in high
quality evidence through randomized controlled trials and
additional randomized controlled trials planned for the near future
with Endologix’s next generation technologies, the accuracy of
which are necessarily subject to risks and uncertainties that may
cause Endologix’s actual results to differ materially and adversely
from the statements contained herein. Some of the potential risks
and uncertainties that could cause actual results to differ
materially and adversely from anticipated results include,
continued market acceptance, endorsement and use of Endologix's
products, the success of clinical trials relating to Endologix’s
products, product research and development efforts, uncertainty in
the process of obtaining and maintaining regulatory approval for
Endologix's products, Endologix’s ability to continue to access the
capital markets, Endologix’s ability to protect its intellectual
property rights and proprietary technologies, and other economic,
business, competitive and regulatory factors. The forward-looking
statements contained in this press release speak only as of the
date of this press release. Endologix undertakes no obligation to
update any forward- looking statements contained in this press
release to reflect new information, events or circumstances after
the date they are made, or to reflect the occurrence of
unanticipated events. Please refer to Endologix's filings with the
Securities and Exchange Commission including its Annual Report on
Form 10-K for the year ended December 31, 2017, and its
Quarterly Reports on Form 10-Q for the quarters ended
March 31, 2018, June 30, 2018, and September 30,
2018 for more detailed information regarding these risks and
uncertainties and other factors that may cause actual results to
differ materially from those expressed or implied.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20181115005944/en/
Endologix, Inc.Vaseem Maboob, CFO(949) 595-7200
Endologix (NASDAQ:ELGX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Endologix (NASDAQ:ELGX)
Historical Stock Chart
From Apr 2023 to Apr 2024